BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 10458242)

  • 1. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
    Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
    J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
    Coiffier B
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma.
    Ogura M; Morishima Y; Kagami Y; Watanabe T; Itoh K; Igarashi T; Hotta T; Kinoshita T; Ohashi Y; Mori S; Terauchi T; Tobinai K
    Cancer Sci; 2006 Apr; 97(4):305-12. PubMed ID: 16630123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.
    Kim KM; Kim HC; Jeon KN; Kim HG; Kang JH; Hahm JR; Lee GW
    Yonsei Med J; 2008 Feb; 49(1):155-8. PubMed ID: 18306483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CD20 monoclonal antibodies for lymphoma therapy.
    Cang S; Mukhi N; Wang K; Liu D
    J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.
    Bobrowicz M; Kusowska A; Krawczyk M; Zhylko A; Forcados C; Slusarczyk A; Barankiewicz J; Domagala J; Kubacz M; Šmída M; Dostalova L; Marhelava K; Fidyt K; Pepek M; Baranowska I; Szumera-Cieckiewicz A; Inderberg EM; Wälchli S; Granica M; Graczyk-Jarzynka A; Majchrzak M; Poreba M; Gehlert CL; Peipp M; Firczuk M; Prochorec-Sobieszek M; Winiarska M
    Oncoimmunology; 2024; 13(1):2362454. PubMed ID: 38846084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.
    Kesavan M; Eyre TA; Collins GP
    Curr Hematol Malig Rep; 2019 Aug; 14(4):207-218. PubMed ID: 31254155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.
    Advani RH; Hong F; Horning SJ; Kahl BS; Manola J; Swinnen LJ; Habermann TM; Ganjoo K
    Leuk Lymphoma; 2012 Apr; 53(4):718-20. PubMed ID: 21916830
    [No Abstract]   [Full Text] [Related]  

  • 10. B cell subsets reconstitution and immunoglobulin levels in children and adolescents with B non-Hodgkin lymphoma after treatment with single anti CD20 agent dose included in chemotherapeutic protocols: single center experience and review of the literature.
    Hlavackova E; Krenova Z; Kerekes A; Slanina P; Vlkova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2024 Jun; 168(2):167-176. PubMed ID: 37227099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
    Dunleavy K; Hakim F; Kim HK; Janik JE; Grant N; Nakayama T; White T; Wright G; Kwak L; Gress R; Tosato G; Wilson WH
    Blood; 2005 Aug; 106(3):795-802. PubMed ID: 15718416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
    Vlasveld LT; Hekman A; Vyth-Dreese FA; Melief CJ; Sein JJ; Voordouw AC; Dellemijn TA; Rankin EM
    Cancer Immunol Immunother; 1995 Jan; 40(1):37-47. PubMed ID: 7530170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.
    Koh LP; Lim LC; Thng CH
    Med Oncol; 2000 Aug; 17(3):225-8. PubMed ID: 10962535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
    Dotan E; Aggarwal C; Smith MR
    P T; 2010 Mar; 35(3):148-57. PubMed ID: 20442809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody therapy of non-Hodgkin's B-cell lymphoma.
    Chinn P; Braslawsky G; White C; Hanna N
    Cancer Immunol Immunother; 2003 May; 52(5):257-80. PubMed ID: 12700943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
    Hiddemann W; Kneba M; Dreyling M; Schmitz N; Lengfelder E; Schmits R; Reiser M; Metzner B; Harder H; Hegewisch-Becker S; Fischer T; Kropff M; Reis HE; Freund M; Wörmann B; Fuchs R; Planker M; Schimke J; Eimermacher H; Trümper L; Aldaoud A; Parwaresch R; Unterhalt M
    Blood; 2005 Dec; 106(12):3725-32. PubMed ID: 16123223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
    McLaughlin P; Grillo-López AJ; Link BK; Levy R; Czuczman MS; Williams ME; Heyman MR; Bence-Bruckler I; White CA; Cabanillas F; Jain V; Ho AD; Lister J; Wey K; Shen D; Dallaire BK
    J Clin Oncol; 1998 Aug; 16(8):2825-33. PubMed ID: 9704735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
    Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
    Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.